Evidence map›Paper›PMID 39855661›Full record

ArticleBMJ open2025

Fingolimod and risk of skin cancer among individuals with multiple sclerosis: a population-based cohort study protocol.

Analisa Jia, Lisa Kuramoto, Amir Khakban, Weng Sut Sio, Anthony Traboulsee, M A De Vera, Jiwon Oh, Jonathan Loree, Roger Tam, Larry D Lynd and 1 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06705608 (Fingolimod and Risk of Skin Cancer Among Individuals with Multiple Sclerosis), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06705608 completednot on this map

Fingolimod and Risk of Skin Cancer Among Individuals with Multiple Sclerosis: a Population-based Cohort Study

TypeobservationalSponsorUniversity of British ColumbiaRan2003 to 2020Enrolled4,000ConditionsMultiple Sclerosis, Skin Cancer, Skin Cancer Melanoma, Skin Cancers - Basal Cell CarcinomaArmsFingolimod, Natalizumab, Dimethyl fumarate (DMF), Alemtuzumab, Teriflunomide
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Analisa JiaCollaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.
Lisa KuramotoCentre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, The University of British Columbia, Vancouver, British Columbia, Canada.
Amir KhakbanCollaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.
Weng Sut SioCollaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.
Anthony TraboulseeDivision of Neurology, Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.
M A De VeraCollaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0002-2205-2683
Jiwon OhDivision of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Jonathan LoreeDivision of Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.
Roger TamSchool of Biomedical Engineering, Department of Radiology, The University of British Columbia, Vancouver, British Columbia, Canada.
Larry D LyndCollaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.
Jacquelyn J CraggCollaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada jacquelyn.cragg@icord.org.ORCID http://orcid.org/0000-0002-6284-938X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLong-term population-based safety studies, applying advanced causal inference techniques, including an active comparator with new-user design, are needed to investigate skin cancer outcomes among individuals with multiple sclerosis (MS) treated with fingolimod. This study aims to describe a protocol for investigating the relationship between fingolimod use and the incidence of skin cancer among individuals with MS. METHODS AND ANALYSIS: We will use population-based administrative health data from two Canadian provinces (British Columbia and Alberta) to conduct an observational cohort 'trial emulation' study with an active comparator and new-user design. Individuals with MS aged ≥18 years will be identified using a validated algorithm. Incident users of fingolimod and active comparators (natalizumab, alemtuzumab, dimethyl fumarate, teriflunomide) will then be identified. The outcome of interest will be skin cancer (melanoma and non-melanoma skin cancers). Survival analysis will be used to estimate HRs and corresponding 95% CIs, adjusted for potential confounders. ETHICS AND DISSEMINATION: Ethics approval for this study was obtained from the University of British Columbia Clinical Research Ethics Board (H24-03199). No personal identifying information will be made available as part of this study. Findings will be disseminated through presentations and peer-reviewed publications. TRIAL REGISTRATION NUMBER: NCT06705608.

Indexed as

Fingolimod HydrochlorideImmunosuppressive AgentsMelanomaMultiple SclerosisSkin NeoplasmsAdultAlbertaBritish ColumbiaCohort StudiesFemaleHumansIncidenceMaleMiddle AgedObservational Studies as TopicResearch DesignFingolimod HydrochlorideImmunosuppressive AgentsDERMATOLOGYDrug TherapyDrug UtilisationMultiple sclerosisONCOLOGY

Identifiers

PMID39855661
PMCPMC11759199

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.